CALX vs NBIX · rev $573.3M vs P/E 45, rev $1.77B
Calix Inc (CALX) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Calix Inc (CALX) is a software - infrastructure company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CALX revenue for 2026-06-27 was $573.3M. Net income was $28.3M. CALX currently screens at market cap $3.25B.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
CALX currently screens at market cap $3.25B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the CALX and NBIX stock pages for the full models.
Not investment advice.